Novel PET Tracers of alpha-synuclein for the diagnosis of Parkinson’s disease
Objective: The aim of our project is to develop small molecular weight compounds (Morphomers™) which bind selectively to alpha-synuclein (aSyn) aggregates, in order to generate…Substantia nigra α4β2 nicotinic cholinergic receptor expression correlates with tremor in Parkinson’s disease
Objective: To investigate the relationship between tremor and α4β2 nicotinic cholinergic receptor (nAChR) expression in brain regions associated with tremor in Parkinson's disease (PD), including…Targeted over-expression with AAV-mediated human α-synuclein in a rat model of Parkinson’s disease – Validation of novel fine motor functional effects
Objective: Targeted over-expression of human α-synuclein using viral-vector mediated gene delivery into the substantia nigra of rats and non-human primates has been reported to lead…Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington’s disease gene carriers
Objective: Using positron emission tomography (PET) with [11C]IMA107, we investigated the in vivo expression of PDE10A in extra-striatal regions in a cohort of 12 early…Metabolic brain changes related to specific cognitive impairment in non-demented Parkinson’s disease patients
Objective: To measure the expression of the Parkinson's disease related cognitive pattern (PDCP) in 18F-FDG-PET brain images of Parkinson's disease (PD) patients and healthy controls…Dysphagia in early stage Huntington’s disease (HD) – Pilot observations from a multimodal imaging study
Objective: To assess the central neural control of swallowing in HD patients with mild dysphagia using a multimodal imaging approach combining qualitative and quantitative swallowing…The evaluation of metabolic differences by using 18F-FDG-PET/CT in demented and non demented Idiophatic Parkinson’s disease patients
Objective: The objective of this study was to identify metabolic group differences between Idiopatic Parkinson's disease patients with dementia (PDD) and without dementia (PD), by…Striatal molecular alterations in Huntington’s disease gene expansion carriers: A systematic review and meta-analysis of PET studies
Objective: To systematically examine the evidence of striatal molecular alterations in premanifest and manifest Huntington's disease gene expansion carriers (HDGECs) as measured by Positron emission…Single-subject FDG PET patterns and cognitive dysfunctions in Parkinson’s disease
Objective: To evaluate [18]FDG-PET single-subject perfusion patterns in Parkinson's disease (PD) patients and their relationship with cognitive dysfunction and progression during five years of follow-up.…Tau pathology in Huntington’s disease: A brief in vivo PET-imaging report
Objective: To assess feasibility of measuring pathological tau deposition in patients with Huntington's disease (HD) using [18F]-AV-1451 (f.k.a. T807) PET. Background: HD is a progressive…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.